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Abstract
Introduction: The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-
like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors.
Furthermore, to be able to disseminate and metastasize, CTC must be able to perform epithelial-mesenchymal
transition (EMT). We studied the expression of three EMT markers and the stem cell marker ALDH1 in CTC from 502
primary breast cancer patients. Data were correlated with the presence of disseminated tumor cells (DTC) in the
bone marrow (BM) and with clinicopathological data of the patients.
Methods: A total of 2 × 5 ml of blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the
detection of EpCAM, MUC-1, HER2 and beta-Actin transcripts. The recovered c-DNA was additionally multiplex
tested for three EMT markers [TWIST1, Akt2, phosphoinositide kinase-3 (PI3Ka)] and separately for the tumor stem
cell marker ALDH1. The identification of EMT markers was considered positive if at least one marker was detected
in the sample. Two BM aspirates from all patients were analyzed for DTC by immunocytochemistry using the pan-
cytokeratin antibody A45-B/B3.
Results: Ninety-seven percent of 30 healthy donor samples investigated were negative for EMT and 95% for
ALDH1 transcripts, respectively. CTC were detected in 97/502 (19%) patients. At least one of the EMT markers was
expressed in 29% and ALDH1 was present in 14% of the samples, respectively. Interestingly, 5% of the ALDH1-
positive and 18% of the EMT-positive patients were CTC-negative based on the cut-off level determined for CTC-
positivity applying the AdnaTest BreastCancer. DTC in the BM were detected in 107/502 (21%) patients and no
correlation was found between BM status and CTC positivity (P = 0.41). The presence of CTC, EMT and ALDH1
expression was not correlated to any of the prognostic clinical markers.
Conclusions: Our data indicate that (1) a subset of primary breast cancer patients shows EMT and stem cell
characteristics and (2) the currently used detection methods for CTC are not efficient to identify a subtype of CTC
which underwent EMT. (3) The clinical relevance on prognosis and therapy response has to be further evaluated in
a prospective trial.
Introduction
Disseminated tumor cells (DTC) in the bone marrow
(BM) and circulating tumor cells (CTC) in blood are
suggested as potential surrogate markers for minimal
residual disease, the precursor of metastatic disease.
Their presence in blood and BM of primary breast
cancer patients represents a strong independent
prognostic factor for reduced disease-free and overall
survival [1-4]. In addition, it has been demonstrated
that tumor cells frequently survive chemotherapy [5,6]
and that their persistence in BM and blood after con-
ventional adjuvant chemotherapy is associated with
poor prognosis [7-9].
One currently discussed hypothesis for the persistence
of these cells is the theory that some DTC or CTC are
cancer stem cells which have been suggested to be the
active source of metastatic spread in primary tumors
[10,11]. For DTC, at least one study has confirmed a
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putative stem cell phenotype showing that CD44+ CD24-
cells were detected in the BM of all patients with cyto-
keratin (CK)-positive cells, whereas their mean preva-
lence among the total number of DTC was 72% [12].
Among CTC identified in patients with metastatic
breast cancer, 32% had the stem cell like phenotype
CD44+CD24- and 17% of the CTC were positive for
one other recently proposed stem cell marker, alde-
hyde dehydrogenase 1 (ALDH1) [13] which has been
associated with poor prognosis in different forms of
breast cancer [14,15]. In addition, CTC from patients
with primary and metastatic breast cancer were shown
to express receptors and activated signaling kinases of
the EGFR/HER2/PI3K/Akt pathway [16], which has
been described as one of the major pathways in the
regulation of mammary stem/progenitor cells, promot-
ing proliferation and the inhibition of apoptosis [17].
We recently demonstrated that CTC in primary breast
cancer patients are generally triple-negative [18], which
is in concordance with the cancer stem cell theory
[19,20].
To be able to disseminate from the primary tumor
and metastasize, tumor cells have to undergo phenotypic
changes, known as epithelial-mesenchymal transition
(EMT), which allows them to travel to the site of metas-
tasis formation without getting affected by conventional
treatment. For CTC, EMT and stem cell features have
recently been documented in 92 breast cancer patients
in all stages of the disease [21]. In metastatic breast can-
cer, we were able to show that a major proportion of
CTC found in the blood of cancer patients shows EMT
and tumor stem cell characteristics and that CTC
expressing EMT and tumor stem cell markers were an
indicator for therapy resistant cell populations and thus,
for an inferior prognosis [22].
So far, no data are available for large cohorts of pri-
mary breast cancer patients. Assuming that metastasis
requires a dissemination of tumor stem cells or tumor
cells showing EMT, we studied the expression of (1) the
EMT markers Akt2, phosphoinositide kinase-3a (PI3K-
a) and the transcription factor TWIST1 and (2) the
stem cell marker ALDH1 in CTC isolated from 502
patients with primary breast cancer. Data were corre-
lated with the presence of DTC in the BM and clinico-
pathological data of the patients.
Materials and methods
Patient population and patient characteristics
The study was conducted at the Department of Obste-
trics and Gynecology in Essen and in the Department of
Obstetrics and Gynecology in Tübingen. In total, 502
primary breast cancer patients (pT1-4, pN0-2, Mo) have
been studied. Patients’ characteristics at the time of
diagnosis are shown in Table 1.
IGROV- cell line
The ovarian cancer cell line was purchased from the
ATCC (American Tissue Culture Collection, Rockville,
MD, USA) and cultured in a humidified incubator at 37°
C in an atmosphere of 5% CO2 and 95% air. The cell
line was maintained in RPMI medium supplemented
with 10% heat-inactivated fetal bovine serum and 1%
penicillin/streptavidin (Biochrom KG, Seromed, Berlin,
Germany).
Healthy controls
A total of 5 ml of blood was collected from 30 healthy
donors aged 23 to 73 years for the determination of spe-
cificity and sensitivity of the applied tests for the deter-
mination of ALDH1 and EMT markers.
Collection and analysis of BM
Between 10 and 20 ml BM were aspirated from the
anterior iliac crests of all primary breast cancer patients
Table 1 Clinical data of patients
Characteristics Total CTC pos In % P-value
Total 502 97 19 -
Tumor Size
pT1 322 58 18 0.32
pT2-4 180 39 22
Nodal Status
Negative 340 65 19 0.79
Positive 159 32 20
Histology
Ductal 392 78 20 0.83
Lobular 77 13 17
Others 30 6 20
Grading
G I 95 18 19 0.68
G II 290 53 18
G III 113 25 22
ER status
Positive 415 77 19 0.34
Negative 87 20 23
PR status
Positive 382 72 19 0.63
Negative 120 25 21
HER2 status
Negative 437 83 19 0.50
Positive 62 14 23
DTC
Negative 367 69 19 0.41
Positive 107 24 21
Subtype by IHC
(ER-, PR-, HER2-) 58 14 24 0.62
(ER-, PR-, HER2+) 17 3 18
(ER+ and/or PR+) 424 80 19
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at the time of surgery and processed within 24 hours.
All specimens were obtained after written informed con-
sent and collected using protocols approved by the insti-
tutional review board (114/2006A/05/2856). Tumor cell
isolation and detection was performed based on the
recommendations for standardized tumor cell detection
recently published by the German Consensus group of
Senology [23]. Details of the staining procedure and cell
detection have been described elsewhere [18].
Sampling of blood
Two × 5 ml EDTA blood was collected for isolation of
CTC before the application of therapeutic substances
with an S-Monovette® (Sarstedt AG & Co., Nümbrecht,
Germany) and stored at 4°C until further examination.
The samples were processed immediately or not later
than four hours after blood withdrawal. An additional
serum sample was collected to determine serum tumor
markers.
Tumor cell enrichment/selection
Blood samples were taken from 502 patients and ana-
lyzed for CTC with the AdnaTest BreastCancer (Adna-
Gen AG, Langenhagen, Germany), which enables the
immunomagnetic enrichment of tumor cells via epithe-
lial and tumor associated antigens. In brief, blood sam-
ples were incubated with a ready-to-use antibody
mixture (against GA733-2 and MUC-1) commercialized
as AdnaTest BreastCancerSelect according to the manu-
facturer’s instructions. The labelled cells were extracted
by a magnetic particle concentrator (MPC). Subse-
quently, mRNA isolation from lysed, enriched cells was
performed according to the manufacturer’s instructions
with the Dynabeads mRNA DIRECT™ Micro Kit (Dynal
Biotech GmbH, Hamburg, Germany) that is included in
the AdnaTest BreastCancerDetect. Reverse transcription
resulted in cDNA, which was the template for tumor
cell detection and characterization by multiplex RT-
PCR. Sensiscript® Reverse Transcriptase (QIAGEN
GmbH, Hilden, Germany) was used for the reverse tran-
scription because of its high sensitivity (recommended
for amounts of < 50 ng RNA) in combination with oligo
(dT) coupled Dynabeads of the mRNA DIRECT™ Micro
Kit (Dynal Biotech GmbH) according to the manufac-
turer’s instructions [24].
Tumor cell detection
The Adnatest BreastCancerDetect was used for the
detection of breast cancer-associated gene expression in
immunomagnetically enriched tumor cells by reverse
transcription and PCR. The analysis of tumor-associated
mRNA isolated from CTC was performed in a multiplex
PCR for the three tumor-associated transcripts HER2,
MUC-1 and GA 733-2 followed by storage of the sam-
ples at 4°C.
The primer sets for the ER and PR receptor were pro-
vided from Adnagen®AG (Langenhagen, Germany). ER
and PR were detected on CTC performed with these
reagents after the preparation of the cDNA and accord-
ing to the instructions of the AdnaTest BreastCancerDe-
tect. PCR was performed with the HotStarTaq Master
Mix (QIAGEN GmbH). Actin was used as an internal
PCR positive control. The thermal profile used for the
nested RT-PCR was as follows: After a 15-minute dena-
turation at 95°C, 37 cycles of PCR were carried out by
denaturation at 94°C for 30 s, annealing/extension at 60°
C for 30 s and elongation for 30 s at 72°C. Subsequently,
termination of the reaction was carried out at 72°C for
five minutes followed by storage of the samples at 4°C.
The primers generate fragments of the following sizes:
GA 733-2: 395 base pairs (bp), MUC-1: 293 bp, HER2:
270 bp, and actin: 114 bp. Visualization of the PCR frag-
ments was carried out with a 2100 Bioanalyzer using the
DNA 1000 LabChips (Agilent Technologies and the
Expert Software Package (version B.02.03.SI307) both
Böblingen, Germany.
Evaluation of data established for CTC
The test is considered positive if a PCR fragment of at
least one tumor associated transcript (MUC-1, GA 773-
2 or HER2) is clearly detected. Using the software pack-
age for evaluation of the data on the Agilent 2100 Bioa-
nalyzer, peaks with a concentration of > 0.15 ng/μl are
positive for the transcripts GA733-2, MUC-1 and HER2.
The AdnaTest TumorStemCell/The AdnaTest EMT
Both tests require the enrichment of CTC from 5 ml
blood using the AdnaTest BreastCancerSelect prior to
the singleplex PCR assay to analyze ALDH1 and the
multiplex PCR assay to analyze EMT markers and actin
as an internal control. Contaminating leukocytes (about
1,500 per sample) are reduced 10-fold by using a special
washing procedure (AdnaWash buffer). This enables the
proper differentiation of EMT and tumor stem cell
expression profiles with a specificity of > 90% which was
confirmed in healthy donor samples.
The thermal profile used for EMT multiplex RT-PCR
was as follows: After a 15-minute denaturation at 95°C,
35 PCR cycles were carried out by denaturation at 94°C
for 30 s, annealing/extension at 60°C for 30 s and elon-
gation for 45 s at 72°C. Subsequently, termination of the
reaction was carried out at 72°C for 10 minutes followed
by storage of the samples at 4°C. The primers generate
fragments of the following sizes: Akt-2: 306 bp, TWIST
1: 203 bp, PI3Ka: 595 bp and Actin: 119 bp,
respectively.
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The thermal profile used for ALDH1 singleplex PCR
was as follows: After a 15-minute denaturation at 95°C,
35 PCR cycles were carried out by denaturation at 94°C
for 30 s, annealing/extension at 51°C for 30 s and elon-
gation for 30 s at 72°C. Subsequently, termination of the
reaction was carried out at 72°C for five minutes fol-
lowed by storage of the samples at 4°C. The generated
fragment size for ALDH1 is 165 bp.
Immunohistochemical analysis of the primary tumor
For each of the 502 patients, the tumor type, TNM-sta-
ging and grading were assessed according to the WHO-
Classification of tumors of the breast [25] and the sixth
edition of the TNM Classification System [26]. The ER
and PR receptor status were routinely determined by
immunohistochemistry in the departments of pathology
of each University Hospital. The DAKO-Score for the
expression of HER2 was determined with the HercepT-
est and FISH analysis in cases of 2+ staining as deter-
mined with the HercepTest was performed as described
elsewhere [27]. Details have been described elsewhere
[18].
Statistical analysis
The chi-squared test or Fisher’s exact test was used to
evaluate the relationship between DTC and CTC and
clinicopathological factors. Statistical analysis was per-
formed by SPSS, version 11.5 (SPSS Inc., Chicago, IL,




A total of 502 patients were included in the study. Clini-
cal data are shown in detail in Table 1. The majority of
patients had tumors smaller than 2 cm and were node-
negative. A total of 415 of 502 (82%) patients were ER-
positive and 382 of 502 patients were PR-positive,
respectively. HER2 expression was present in 62 of 502
patients (12%). Classifying tumors in subtypes based on
their ER, PR and HER2 expression, 424/502 (85%) of the
tumors were ER and/or PR positive, 58/502 (12%) were
triple-negative (ER-/PR-/HER2-) and 17 tumors (3%)
only expressed HER2 (ER-/PR-/HER2+).
Correlation of CTC with established prognostic markers
A blood sample was regarded CTC positive if at least
one of the three markers EPCAM, MUC-1 or HER2 was
expressed. The overall detection rate for CTC was 19%
(97/502 patients). The presence of CTC did not signifi-
cantly correlate with any of the clinicopathological fac-
tors. DTC were found in 107/502 (21%) patients. No
correlation could also be observed between positive BM
status and CTC positivity (P = 0.41; Table 1).
Correlation of CTC and EMT markers/ALDH1
All samples were further examined for ALDH1 and
EMT markers and correlated with the presence of CTC.
The complete data set for the detection of CTC, the
expression for ALDH1 as well as the EMT markers
could be determined in 446/502 patients. At least one of
the EMT markers was expressed in 29% (Akt2 27%;
PI3K 17%; TWIST 1%) and ALDH1 was present in 14%
of the samples, respectively (Figure 1). In the CTC+
group, 66 of 92 patients (72%) were positive for at least
one of the EMT markers and 42 of 92 patients (46%)
were positive for ALDH1, respectively. In the CTC-
group, the percentages were 18% (63 of 354 patients)
and 5% (19/353 patients) (Figure 2). Table 2 shows a
more detailed analysis of the distribution of the indivi-
dual markers among the CTC+ and CTC- groups. In the
CTC+ group, the expression rates for the EMT markers
were 1% (TWIST), 70% (Akt2), and 52% (PI3Ka) and in
the CTC- group, the percentages were 1%, 16%, and 8%,
respectively (Table 2). Positivity with EMT markers or
ALDH1 was not associated with any of the clinicopatho-
logical factors.
Discussion
Enumeration of CTC in breast cancer, using the FDA
approved CellSearch technology, has been well estab-
lished in several clinical studies, showing a correlation
with decreased progression-free survival and overall sur-
vival in primary as well as in metastatic breast cancer
before the initiation of treatment [28-31]. Monitoring
studies provided valuable clinical information for the
management of breast cancer patients and an ongoing
prospective randomized clinical trial is now addressing
the question whether to change an existing treatment
protocol according to the persistence of CTC after three
to five weeks of therapy instead of waiting for clinical
and radiologic evidence of progression in metastatic
breast cancer patients [SWOG S0500, clinicaltrials.gov,
identifier: NCT00382018].
Despite the prognostic impact of CTC counts in
breast cancer, mainly using EpCAM-based capturing
methods, it has been shown that this procedure is not
able to detect the entire, highly heterogenous population
of CTC [32,33]. In addition, their biological features are
poorly understood and it is assumed that only a few
CTC are able to grow into clinically evident metastases
[34]. Furthermore, the current belief is that EMT pro-
cesses, also in the primary tumor, play key roles in the
invasion steps of the metastatic cascade involved in the
generation of the so called breast cancer stem cells [35].
Taking all these considerations into account, we
applied a multimarker RT-PCR assay for the identifica-
tion of CTC-associated transcripts, using an antibody
‘cocktail’ for capturing CTC of epithelial origin. This
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test procedure has been successfully applied for the
detection and characterization of CTC in gynaecological
cancers and the prognostic value has been shown for
monitoring of metastatic breast cancer patients and
recently for primary ovarian cancer patients where the
detection of CTC before surgery and after platinum-
based chemotherapy significantly correlated with a
reduced overall survival [18,22,36,37]. Interestingly, a
very recent publication demonstrated that the AdnaTest
complements the CellSearch system by improving the
overall detection rate and permitting the assessment of
genomic markers in CTC in metastatic breast cancer
patients [38]. Using this technology, we demonstrate
here, by the analysis of 502 primary breast cancer
patients, that a subset of patients shows EMT and stem
cell characteristics and that the currently used detection





















Figure 2 Expression of EMT-markers and ALDH1 in CTC+ and CTC- patients. In the CTC+ group, 66 of 92 patients (72%) were positive for at
least one of the EMT markers and 42 of 92 patients (46%) were positive for ALDH1, respectively. In the CTC- group, the percentages were 18%
(63 of 354 patients) and 5% (19/353 patients).
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methods for CTC are not efficient to identify a subtype
of CTC which underwent EMT or display a cancer stem
cell phenotype. To our knowledge, this is the biggest
patient cohort published up to now, analyzing these
CTC characteristics.
At least one of the EMT markers was expressed in
29% and ALDH1 was present in 14% of the samples,
respectively. Very recently published data in smaller
patient groups support our data. Raimondi et al. investi-
gated the expression of EMT and stemness markers in
92 breast cancer patients at all stages of the disease.
Using the standard definition of CTC as EpCAM+/CK
+/CD45-, the authors failed to find them in 31/92 (34%)
patients. The absence of CTC was defined as the lack of
expression in the enriched EpCAM-positive fraction.
Nevertheless, in 12/31 (38%) of these CK-negative cells
they found the expression of EMT markers, specifically
vimentin and fibronectin. They concluded that current
CTC detection methods underestimate the most impor-
tant subpopulations of CTC involved in cancer dissemi-
nation, which often share EMT and stemness features
[21]. These data are in accordance with our findings,
showing that 5% of the ALDH1-positive and 18% of the
EMT-positive patients were CTC-negative based on the
cut-off level determined for CTC-positivity applying the
AdnaTest BreastCancer.
Reuben et al. assessed the presence of Aldeflour
+epithelial (CD326+CD45dim) cells for the presence of
the CD44+CD24lo phenotype in the BM of patients
with primary breast cancer. They report that the percen-
tage of CD44+CD24lo cancer stem cells in the BM is
higher in primary breast cancer patients with high risk
tumor features. Furthermore, patients who received
neoadjuvant chemotherapy were more likely to have
percentages of Aldeflour+ epithelial cells than the high-
est level of healthy donors [11].
In a retrospective study, including 292 metastatic
breast cancer patients, CTC were enumerated before
patients started a new line of treatment using the Cell-
Search System. CTC were not detected in 36% of the
patients. In multivariate analysis, brain metastasis and
bone involvement remained independent variables asso-
ciated with undetectable CTC status. Also, patients with
negative hormone receptors, high tumor grade, triple-
negative disease and inflammatory breast cancer had
increased probabilities for undetectable CTC. The
authors suggested that these findings could be due to an
under estimation of CTC by CellSearch due partly to
CTC undergoing EMT [39]. A second observation of
this study was a significant association of the absence of
bone metastasis and undetectable CTC status as well.
This again raises the frequently asked question of
whether BM analysis for the detection of DTC can be
replaced by blood sampling for the detection of CTC. In
our present study, as well as in our recently published
study, comparing DTC and CTC in 431 primary breast
cancer patients, we documented a weak concordance
between the presence of these cells in BM and blood,
concluding that the biology of these cells may be differ-
ent [18]. These data are in accordance with other com-
parison studies where, in general, the correlation
between DTC and CTC was shown to be low [40-43].
In brief, the detection of CTC appeared to be less sensi-
tive and less prognostic and the prognosis of women
with primary breast cancer depended on DTC rather
than CTC. However, two other recently published stu-
dies found that the determination of CTC status by RT-
PCR conveyed clinically relevant information that was
not inferior to DTC status in breast cancer [44,45]. Con-
clusively, blood analysis can give complementary infor-
mation to that obtained by BM analysis.
There are different explanations for this phenomenon.
1) The absence of CTC as described above by Mego et
al. may also be dependent on the inadequacy of CTC
standard selection procedures. Most selection proce-
dures are based only on EpCAM, which possibly gets
lost during the progress of EMT. 2) EMT cells, degrad-
ing the surrounding matrix, also allow the detachment
and dissemination of non-EMT tumor cells. Thus, DTC
and CTC may reflect the heterogeneous tumor cell
population of the primary tumor, including differen-
tiated and more stem cell-like tumor cells. 3) One may
also speculate that bone metastasis requires a different
mechanism of dissemination or epithelial differentiation.
The PTEN/Akt/mTOR pathway has been described: 1)
as one of the major pathways in the regulation of mam-
mary stem/progenitor cells, 2) to confer resistance to
conventional therapy, and 3) to play a central role in the
viability and maintenance of cancer stem cells in breast,
promoting proliferation and the inhibition of apoptosis
[17,46]. Furthermore, cells undergoing EMT have been
shown to develop resistance to anti-cancer agents [47].
Only a few studies have addressed these aspects in
CTC. By analyzing peripheral blood mononuclear cell
cytospins from 28 CK-positive and 17 CK-negative
patients samples using confocal laser scanning micro-
scopy, phosphorylated PI-3 kinase (phospho PI3K) was
Table 2 Expression of EMT markers and ALDH1 in CTC-
positive and CTC- negative patients




354 63 (18%) 57 (16%) 28 (8%) 2 (1%) 353 19 (5%)
CTC
pos
92 66 (72%) 64 (70%) 48
(52%)







3 (1%) 445 61 (14%)
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documented in 15 of 17 CK- positive samples [48]. In a
recent study, the authors analyzed peripheral blood
mononuclear cells from 32 cytokeratin-19 mRNA-posi-
tive patients with early and 16 patients with metastatic
breast cancer and reported that phospho PI3K/Akt were
identified in a significant proportion of CTC [16]. These
data support the data of this study as well as our
recently published data in metastatic breast cancer
showing that a major proportion of CTC expressed
PI3K, Akt2 as well as the transcription factor TWIST
and ALDH1 which was associated with therapy resis-
tance and an inferior prognosis [22].
In summary, the expression of stemness and EMT
markers in CTC has been found associated with resis-
tance to conventional anti-cancer therapies and treat-
ment failure, highlighting the urgency of improving
tools for detecting and eliminating minimal residual dis-
ease [49]. Consequently, the detection of stemness-like
cells is highly recommended for therapeutic and diag-
nostic implications. Signaling pathways that maintain
cancer stem cells are attractive targets for these thera-
pies. Preclinically, everolimus (RAD001), an oral inhibi-
tor of mTOR acting downstream of the PI3K/AKT
pathway, has been shown to reverse resistance to
tamoxifen. In a phase II study, RAD001 combined with
tamoxifen provided significant improvement in the six-
month clinical benefit rate compared to tamoxifen alone
[50]. Furthermore, RAD001 had effective inhibitory
effects on cancer stem cells in vitro and in vivo and,
combination treatment with RAD001 and docetaxel or
Herceptin® may be effective in refractory metastatic
breast cancer [51]. In addition, combinational therapy
aimed at Shh and mTOR signaling inhibition, together
with standard chemotherapy, proved to be capable of
selectively eliminating cancer stem cells [52].
Li et al. demonstrated that the remaining tumorigenic
cells after chemotherapy had unique properties of
enhanced self-renewal as demonstrated by formation of
mammospheres and increased propensity for tumor for-
mation. In addition, lapatinib did not lead to an increase
in these tumorigenic cells, and thus, in combination
with conventional therapy, specific pathway inhibitors
may provide a therapeutic strategy for eliminating these
cells to decrease recurrence and improve long-term sur-
vival [53]. Another promising agent is salinomycin
where global gene expression analyses showed that sali-
nomycin treatment resulted in the loss of expression of
breast cancer stem cells [54].
Conclusions
The cancer stem cell hypothesis is a new paradigm that
could have a major impact on the treatment of disease
by suggesting a new target for cancer therapy. Current
treatments of cancer have shown efficacy in removing
the bulk of differentiated cancer cells while failing to
eliminate the cancer stem cells responsible for tumor
relapse. Targeting residual cells with stem cell self-
renewal properties in combination with conventional
chemotherapy may provide a specific approach to pre-
vent cancer recurrence and improve long-term survival.
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